Status:
COMPLETED
Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Invasive Fungal Infections
Eligibility:
All Genders
Brief Summary
Voriconazole is an effective antifungal agent and may decrease morbidity and mortality for patients with invasive fungal infections. It is metabolized via liver enzymes. However, these enzymes exhibit...
Detailed Description
The incidence of opportunistic, invasive fungal infections has dramatically increased over the past two decades and they cause high morbidity and mortality in a variety of patient populations. Voricon...
Eligibility Criteria
Inclusion
- Hospitalization patient or ambulatory patients
- Patients with invasive fungal infections
- Patients who take PO/IV voriconazole more than 3 days
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00745992
Start Date
October 1 2008
End Date
July 1 2011
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100